Search | Médecins Sans Frontières Access Campaign

57 results found

GeneXpert test technology has revolutionised the diagnosis of TB, allowing detection of the TB bacterium, and its resistance to drugs, in only two hours.

Press release |

07 November 2023

MSF responds to WHO’s annual global TB report: implores governments to use recent TB wins to beat back deadly infectious disease

Recent price reductions to WHO-recommended TB tests and treatment should enable more countries to make these vital medical tools available

Tags Tuberculosis drug-resistant TBtuberculosis GeneXpertbedaquiline World Health Organization

Press release |

16 January 2023

India must reject Johnson & Johnson’s attempt to extend monopoly on lifesaving TB drug bedaquiline

Ahead of the final hearing on a patent challenge by two TB survivors, MSF urges the Indian Patent Office to reject Johnson & Johnson’s secondary patent application so that other manufacturers may enter the supply chain with more ...

Tags Tuberculosis tuberculosis bedaquiline patent opposition World Health Organization India

A Nurse examines medications in the storeroom at the TB Practecal Warehouse in Nukus, Uzbekistan.

Press release |

03 May 2022

MSF responds to new WHO guidance recommending vastly shorter, improved and better-tolerated treatment for multidrug-resistant TB

The World Health Organization (WHO) announced global treatment guidance with new, safer and more effective six-month oral treatment regimen for multidrug-resistant tuberculosis.

Tags Tuberculosis tuberculosis pretomanidlinezolidbedaquiline World Health Organization

MSF Counsellor, counselling parents of a six-year-old girl with drug-resistant TB at MSF independent Clinic, Mumbai- India

Press release |

03 September 2021

Lifesaving TB medicines must be affordable and available to make all-oral treatments for children a reality

The WHO recently released new rapid guidance recommending that children of all ages with drug-resistant tuberculosis (DR-TB) have access to all-oral treatment using the drugs bedaquiline and/or delamanid. However paediatric ...

Tags Tuberculosis tuberculosis bedaquilinedelamanid World Health OrganizationJohnson & Johnson

Iryna Shchyra, deputy head of the pharmacy at the Zhytomyr Regional TB Dispensary, holds a bottle of bedaquiline.

Press release |

22 December 2018

As WHO issues new TB treatment guidelines, MSF calls for urgent scale-up of all-oral treatment

MSF welcomes new WHO treatment guidelines that recommend drug-resistant tuberculosis be treated with oral drugs only, including newer, more potent drugs with fewer side effects, such as bedaquiline.

Tags Tuberculosis drug-resistant TB bedaquilinedelamanid World Health OrganizationJohnson & Johnson

Nischaya, an XDR-TB patient, looking at her TB medication at the MSF clinic in Mumbai. Photograph by Atul Loke

Press release |

25 October 2018

Activists urge national TB programs and treatment providers to discontinue use of harmful injectable agents in TB treatment

Tags Tuberculosis drug-resistant TB linezolidbedaquilinedelamanid Union Conference on Lung HealthTreatment Action GroupWorld Health Organization Netherlands

Image of bedaquiline, TB drug at the MSF project in Osh, Kyrgyzstan, 2017.

Press release |

23 October 2018

MSF warns high prices of tuberculosis drugs restrict people's access to best drug-resistant TB treatment

We call on US pharma corporation Johnson & Johnson to cut key TB drug price in half

Tags Tuberculosis drug-resistant TB bedaquilinedelamanid patent pool Union Conference on Lung HealthWorld Health OrganizationJohnson & Johnson DRTB Drugs Under the Microscope Netherlands

A sputum sample analysis at the Blue House Clinic in Kenya, 2011.

Press release |

25 September 2018

Global leaders must make bold commitments at first-ever UN tuberculosis summit

Urgent need to scale up newer tools available today to save lives; and develop a fast, safe and simple cure for TB.

Tags Tuberculosis drug-resistant TBtuberculosis bedaquiline diagnostic testsresearch and development (R&D) World Health Organization

Kibera is one of the largest slums in Kenya. Here, MSF offers care to a neglected population isolated from basic healthcare standards due to hardships of poverty, Kenya 2011.

Press release |

18 September 2018

MSF response to release of WHO’s Global Tuberculosis Report 2018

The report highlights sluggish global progress on TB, indicating that countries will not be able to meet their targets in the ‘End TB’ strategy at this slow pace.

Tags Tuberculosis drug-resistant TBtuberculosis bedaquiline diagnostic tests World Health Organization

XDR-TB patient Hanif, taking his daily TB medication at home in the Govandi area of Mumbai, 2016.

Press release |

17 August 2018

MSF applauds the World Health Organization’s move to recommend improved tuberculosis treatment options

MSF calls on Johnson & Johnson to make key drug bedaquiline affordable for all people who need it.

Tags Tuberculosis drug-resistant TB bedaquiline World Health OrganizationJohnson & Johnson

Issue brief |

23 July 2018

Stopping senseless deaths

This issue brief analyses access barriers to affordable, lifesaving diagnostics and treatments for HIV and OIs, including adult and paediatric formulations of dolutegravir – a highly effective and tolerable HIV integrase inhibitor that ...

Tags HIV/AIDS drug-resistant TBHIV/AIDSΚaposi's sarcomatuberculosis valganciclovirantiretroviral medicinesbedaquiline access to medicinesfree trade agreement International AIDS Conference

Press release |

30 October 2017

Médecins Sans Frontières response to the World Health Organization Global Tuberculosis Report

Tags Tuberculosis drug-resistant TB bedaquilinedelamanid World Health Organization

Simphiwe holds his first delamanid tablets, which have now been included into his treatment regimen for XDR-TB, October 2016.

Press release |

26 October 2016

MSF reports on use of the new TB drugs bedaquiline and delamanid

Tags Tuberculosis drug-resistant TBtuberculosis bedaquilinedelamanid Union Conference on Lung HealthWorld Health Organization

Press release |

24 November 2015

MSF reaction to latest UNAIDS report on global progress of scaling up life-saving HIV treatment

Tags HIV/AIDS HIV/AIDS antiretroviral medicines UNAIDSWorld Health Organization

MSF Expert Client performing a HIV test at the MSF Dipping Tank community testing campaign at Nhletsheni, in Shiselweleni region, south of Swaziland.

Press release |

20 July 2015

MSF response to START trial data showing all people with HIV should be treated immediately

Tags HIV/AIDS HIV/AIDS antiretroviral medicines International AIDS Conference Eswatini

The Accession Support Group and Community (GAAC) meet together for lectures and emotional support from peers in Maputo, Mozambique, 2012.

Press release |

02 July 2013

Generic competition pushing down HIV drug prices, but patents keep newer drugs unaffordable

Tags HIV/AIDSIntellectual property and trade HIV/AIDS antiretroviral medicines International AIDS Conference

Ma Htwe Myint, 38, holds her 16 month old baby Thar Nge. He is co-infected with HIV and TB.

Press release |

01 July 2013

MSF applauds new WHO recommendations for accelerating HIV treatment in developing countries

Tags HIV/AIDS HIV/AIDS antiretroviral medicines World Health Organization

Issue brief |

26 March 2013

Buruli Ulcer: Ending the Neglect of a Disease That Impacts the Young

Tags Intellectual property and tradeResearch and developmentTropical & neglected diseases Buruli ulcerco-infectionneglected diseases antiretroviral medicines World Health Organization

Press release |

05 March 2013

MSF Research Points to Ways to Expand Viral Load Testing in Developing Countries

Tags HIV/AIDSIntellectual property and trade HIV/AIDS antiretroviral medicines diagnostic tests World Health Organization Malawi

Press release |

26 July 2012

Middle-Income Countries Flex Muscles to Overcome Patents in Face of Unaffordable Drug Prices

Tags HIV/AIDSIntellectual property and trade antiretroviral medicinesFDCs compulsory licence International AIDS Conference India

Date

Primary topics

Types of content

Products

Diseases

General Terms

Geography

Campaigns

Institutions & Events

Report series

Miscellaneous

MSF responds to WHO’s annual global TB report: implores governments to use recent TB wins to beat back deadly infectious disease

India must reject Johnson & Johnson’s attempt to extend monopoly on lifesaving TB drug bedaquiline

MSF responds to new WHO guidance recommending vastly shorter, improved and better-tolerated treatment for multidrug-resistant TB

Lifesaving TB medicines must be affordable and available to make all-oral treatments for children a reality

As WHO issues new TB treatment guidelines, MSF calls for urgent scale-up of all-oral treatment

Activists urge national TB programs and treatment providers to discontinue use of harmful injectable agents in TB treatment

MSF warns high prices of tuberculosis drugs restrict people's access to best drug-resistant TB treatment

Global leaders must make bold commitments at first-ever UN tuberculosis summit

MSF response to release of WHO’s Global Tuberculosis Report 2018

MSF applauds the World Health Organization’s move to recommend improved tuberculosis treatment options

Stopping senseless deaths

Médecins Sans Frontières response to the World Health Organization Global Tuberculosis Report

MSF reports on use of the new TB drugs bedaquiline and delamanid

MSF reaction to latest UNAIDS report on global progress of scaling up life-saving HIV treatment

MSF response to START trial data showing all people with HIV should be treated immediately

Generic competition pushing down HIV drug prices, but patents keep newer drugs unaffordable

MSF applauds new WHO recommendations for accelerating HIV treatment in developing countries

Buruli Ulcer: Ending the Neglect of a Disease That Impacts the Young

MSF Research Points to Ways to Expand Viral Load Testing in Developing Countries

Middle-Income Countries Flex Muscles to Overcome Patents in Face of Unaffordable Drug Prices